CAJ | 학술논문

目的：观察聚乙二醇干扰素α--2a联合利巴韦林治疗慢性丙型肝炎的疗效和安全性．方法将106例慢性丙型肝炎患者随机分为2组，给予抗病毒治疗，实验组给予皮下注射聚乙二醇干扰素α-2a 180μg，每周1次；对照组给予皮下注射干扰素α-1b 5MIU，隔日1次，2组均按体重同时服用联合利巴韦林900～1200 mg，每天1次，疗程48周．分别在治疗前、治疗第4周、12周、24周、治疗结束时、治疗结束后24周测定患者血清HCV-RNA水平，同时观察不良反应．结果实验组的快速病毒学应答率（RVR）为77.4％，完全早期病毒学应答率（cEVR）为83.0％，治疗结束应答率（ETVR）为90.6％，治疗结束后随访24周持续应答率（SVR）为84.9％，明显优于对照组．结论聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎具有良好的抗病毒疗效，安全性较好．
목적：관찰취을이순간우소α--2a연합리파위림치료만성병형간염적료효화안전성．방법장106례만성병형간염환자수궤분위2조，급여항병독치료，실험조급여피하주사취을이순간우소α-2a 180μg，매주1차；대조조급여피하주사간우소α-1b 5MIU，격일1차，2조균안체중동시복용연합리파위림900～1200 mg，매천1차，료정48주．분별재치료전、치료제4주、12주、24주、치료결속시、치료결속후24주측정환자혈청HCV-RNA수평，동시관찰불량반응．결과실험조적쾌속병독학응답솔（RVR）위77.4％，완전조기병독학응답솔（cEVR）위83.0％，치료결속응답솔（ETVR）위90.6％，치료결속후수방24주지속응답솔（SVR）위84.9％，명현우우대조조．결론취을이순간우소α-2a연합리파위림치료만성병형간염구유량호적항병독료효，안전성교호．
Objective To observe the efficacy and safety of pegylated interferon apha-2a combined with ribavirin in the treatment of chronic hepatitis C.Methods One hundred and six patients with chronic hepatitis C were divided into 2 groups randomly.Patients in the observation group were treated with pegylated interferon alpha-2a,and patients in the control group were treated with interferon alpha-1b.All patients were given ribavirin according to the weight,and the treatment course was 48 weeks.HCV-RNA was tested before treatment,4 weeks, 12weeks and 24 weeks after the start of treatment,end of treatment,24 weeks after the end of treatment.The adverse reactions were also observed.Results In the observation group,the rapid virological response (RVR) was 77.4%,the complete early virological response (cEVR) was 83.0%,the end treatment virological response (ETVR) was 90.6%, the sustained virological response (SVR) of 24 weeks after the end of treatment was 84.9%.and these rates were significantly higher than the control group.All patients received the whole course of treatment.Condusion Treatment of chronic hepatitis C with pegylated interferon apha-2a combined with ribavirin is effective and safe.